China SFDA Calls For Release Of Materials To Ease Hemophilia Treatment Shortage (China)
This article was originally published in PharmAsia News
Executive Summary
China's State FDA says it has asked four blood-products companies in the country to release the raw materials used to make the clotting factor VIII to help eliminate a shortage of the materials needed to treat hemophilia. The agency sent the firms a notice seeking cryoprecipitate, a frozen blood product produced from plasma, to make them available to the three companies that produce factor VIII. The shortage was caused in part to a 50 percent drop in the plasma supply last year. (Click here for more )